Search Results

USGI Medical, Inc., the pioneer of incisionless weight loss procedures and devices, announced that the United States Food and Drug Administration has approved an Investigational Device Exemption application to conduct a pivotal study of its POSE2.0®incisionless procedure for primary obesity.

USGI Medical, Inc. (USGI) announced today the United States Food and Drug Administration (FDA) acknowledged the successful completion of a pilot study of its incisionless, endoscopic gastroplasty procedure, known as POSE2.0®, which evaluated weight loss in adults suffering from obesity (body mass index [BMI] 35-40 kg/m²) who have an obesity-related comorbidity, such as diabetes or hypertension.

USGI Medical, Inc, a cutting-edge company advancing incisionless endoluminal procedures, announced the retirement of President and CEO Mr. Carlos Babini.

USGI Medical, Inc, (USGI) a cutting-edge company advancing incisionless endoluminal procedures, announced that the Food and Drug Administration (FDA) approved the expansion of a US- pilot study of the Company’s non-invasive, endoscopic procedure, known as POSE 2.0 , designed to evaluate weight loss for adults suffering from obesity with a body mass index (BMI) of 35 to 40 kg/m² and an obesity-related comorbidity, such as diabetes or hy